Document:

<PAGE>

                                                                    EXHIBIT 10.2

                                                               Option No. ISO-__

                         INSPIRE PHARMACEUTICALS, INC.

                            INCENTIVE STOCK OPTION

     Inspire Pharmaceuticals, Inc. (the "Company"), a Delaware corporation, as
an incentive and inducement to___________________ (the "Optionee"), who is
presently an employee of the Company, to devote [his or her] best efforts to the
affairs of the Company, which incentive and inducement the Board of Directors of
the Company (the "Board") has determined to be sufficient consideration for the
grant of this Option, hereby grants to the Optionee the right and option (the
"Option") to purchase from the Company up to____________shares of its Common
Stock, $0.001 par value (the "Stock"). This Option is granted under, and is
subject to, the provisions of the Company's 1995 Stock Plan, as amended from
time to time (the "Plan") and shall be exercisable only on the following terms
and conditions:

1 .  The price ("Strike Price") to be paid for each share of Stock upon exercise
of the whole or any part of this Option shall be $0._____, which is not less
than 100% of the fair market value of a share of Stock on the date hereof.

2.   This Option may be exercised, at any time after________________ (a "Vesting
Date"), as to_______ shares, then for____ months thereafter on the _____ day of
each month (each, a "Vesting Date"), this Option may be exercised as to ______
shares, and on the final month of vesting, this Option may be exercised as to
the remaining______ shares (the "Exercise Period"); provided, however, that this
Option may not be exercised as to any shares after the expiration of ten years
from the date hereof.

3.   This Option may be exercised at any time and from time to time, subject to
the limitation of Section 2 above, up to the aggregate number of shares
specified herein, but in no event for the purchase of other than full shares.
Written notice of exercise shall be delivered to the Company specifying the
number of shares with respect to which the Option is being exercised and a date
not later than fifteen days after the date of the delivery of such notice as the
date on which the Optionee will take up and pay for such shares. On the date
specified in such notice, the Company will deliver to the Optionee a certificate
for the number of shares with respect to which the Option is being exercised
against payment therefor in cash or by certified check.

4.   The Optionee shall not be deemed, for any purpose, to have any rights
whatever in respect of Option Shares to which the Option shall not have been
exercised and payment made as aforesaid. The Optionee shall not be deemed to
have any rights to continued employment by virtue of this Option.

5.   In the event that the Board, in its discretion, determines that any stock
dividend, split-up, combination or reclassification of shares, recapitalization
or other similar capital change affects the

                                      -1-
<PAGE>

Stock such that adjustment is required in order to preserve the benefits or
potential benefits of this Option, the maximum aggregate number and kind of
shares or securities of the Company subject to this Option, and the Strike Price
of this Option, shall be appropriately adjusted by the Board (whose
determination shall be conclusive) so that the proportionate number of Option
Shares or other securities subject to this Option and the proportionate interest
of the Optionee shall be maintained as before the occurrence of such event.

6.   In the event of a consolidation or merger of the Company with another
corporation, or the sale or exchange of all or substantially all of the assets
of the Company, or a reorganization or liquidation of the Company, the Optionee
shall be entitled to receive upon exercise and payment in accordance with the
terms of the Option the same shares, securities or property as he or she would
have been entitled to receive upon the occurrence of such event if he or she had
been, immediately prior to such event, the owner of the number of Option Shares.
In lieu of the foregoing, however, the Board may upon written notice to the
Optionee provide that, unless theretofore exercised, this Option shall expire as
of the earlier of the Expiration Date or the date specified in such notice which
may not be less than 20 days after the date of such notice. In connection with
such notice, the Board may in its discretion accelerate or waive any deferred
Vesting Date.

7.   During the Optionee's lifetime, this Option shall be exercisable only by
such Optionee or, in the case of his or her legal incapacity, his or her
guardian or legal representative. This Option shall be transferable by the
Optionee only by will or the laws of descent and distribution. After the
Optionee's death, the Option shall be exercisable only by the person or persons
entitled to do so under the Optionee's last will and testament or if the
Optionee fails to make a testamentary disposition of the Option or dies
intestate, by the person or persons entitled to receive the Option under any
applicable laws of descent and distribution. In no event shall the Option be
exercisable by any such transferee described above to a greater extent than the
Option could have been exercised by the Optionee immediately prior to his or her
death or the effective date of his or her termination of employment due to
Disability, as defined in Section 22(e)(3) of the Code (as applicable). The
Board shall have the right to require evidence to its satisfaction of the rights
of any person or persons seeking to exercise the Option hereunder, e.g., an
                                                                   ---
authenticated copy of the will. Any attempted assignment, transfer, pledge,
hypothecation or other disposition of this Option contrary to the provisions
hereof, and the levy of any execution, attachment or similar process upon the
Option, shall be null and void and without effect. Any transferee described
above shall be treated as the Optionee for purposes of all other provisions of
this Option Agreement and the terms of the Plan.

8.   If the Optionee terminates employment during the Exercise Period, such
period shall be adjusted as follows, except that in no event shall the Exercise
Period be extended beyond the Expiration Date:

     (a)  The Exercise Period shall end immediately upon the date of the
          Optionee's breach of any agreement, covenant or representation by and
          between the Optionee and the Company, including but not limited to any
          promise or warrant made as consideration for this amendment or the
          terms of any severance agreement.

                                      -2-
<PAGE>

     (b)  The Exercise Period shall end immediately upon the effective date of
          the Optionee's termination of employment by his or her: (i)
          voluntary resignation in violation of any agreement to remain in the
          employ of the Company; (ii) involuntary "Discharge for Cause" for
          reasons which may include, without limitation, any illegal or improper
          conduct that injures or impairs the reputation, goodwill, or business
          of the Company, involves the misappropriation of funds of the Company,
          or the misuse of data, information or documents acquired in connection
          with employment by the Company, or violates any other directive or
          policy promulgated by the Company; (iii) resignation in anticipation
          of Discharge for Cause; or (iv) resignation accepted by the Company in
          lieu of a formal Discharge for Cause.

     (c)  The Exercise Period shall end three months after the effective date of
          the Optionee's termination of employment for any reason OTHER THAN:
          (i) by transfer to an affiliated corporation which owns directly or
          indirectly 50 percent or more of the total combined voting power of
          the Company or in which the Company owns directly or indirectly 50
          percent or more of the total combined voting power or has a
          significant financial interest as determined by the Board
          ("Affiliate"); or (ii) any reason for which the Option would expire
          immediately, as described under this Section.

     (d)  The Exercise Period shall end twelve months after the effective date
          of the Optionee's death or termination of employment due to
          Disability, subject to such proof of Disability as the Board may
          require.

9.   It shall be a condition of exercise hereunder that:

     (a)  The Company may, in its discretion, require that in the opinion of
          counsel for the Company the proposed purchase of Option Shares shall
          be exempt from registration under the Securities Act of 1933, as
          amended;

     (b)  The Optionee shall have made such undertakings and agreements with the
          Company as the Company may reasonably require, and that such other
          steps, if any, as counsel for the Company shall deem necessary to
          comply with any law, rule or regulation applicable to the issue of
          such shares by the Company shall have been taken by the Company or the
          Optionee, or both;

     (c)  The certificates representing the shares purchased under this Option
          may contain such legends as counsel for the Company shall deem
          necessary to comply with the applicable law, rule or regulation;

     (d)  The Optionee shall execute and deliver to the Company a counterpart of
          the Amended and Restated Stockholders Agreement among the Company and
          certain of its

                                      -3-
<PAGE>

          stockholders dated March 10, 1995, and any amendment thereto or
          restatement or replacement thereof, pursuant to which the Optionee
          shall be subject to all provisions therein applicable to holders of
          Common Stock of the Company; and

     (e)  The Option shall, if the Company so requests, provide payment of all
          state and federal taxes imposed upon the exercise of this Option and
          the issue of the shares covered hereby.

10.  This Option is issued pursuant to the terms of the Plan. This Certificate
does not set forth all of the terms and conditions of the Plan, which are
incorporated herein by reference. Copies of the Plan may be obtained upon
written request without charge from the Treasurer of the Company.

11.  This Option is intended to be treated as an Incentive Stock Option.

     (a)  The Optionee agrees to notify the Company in writing within 30 days of
          the disposition of one or more shares of Stock which were transferred
          to him or her pursuant to the exercise of this Option if such
          disposition occurs within two years from the Date of Grant of this
          Option or within one year after the transfer of such shares.

     (b)  The Optionee acknowledges that:

          (i)   In the event the Optionee terminates employment with the Company
                or an Affiliate for reasons other than death or Disability, this
                Option shall cease to be eligible for tax treatment as an
                Incentive Stock Option, unless it is exercised within three
                months from the date of such termination; and.

          (ii)  In the event the Optionee dies or terminates employment due to
                Disability, this Option shall cease to be eligible for tax
                treatment as an Incentive Stock Option, unless it is exercised
                within twelve months from the date of death or such termination
                due to Disability.

12.  This Option Agreement may be amended only by a written agreement executed
by the Company and the Optionee. The Company and the Optionee acknowledge that
changes in federal tax laws enacted subsequent to the Date of Grant, and
applicable to stock options, may provide for tax benefits to the Company or the
Optionee. In that event, the Company and the Optionee agree that this Option
Agreement may be amended as necessary to secure for the Company and the Optionee
any benefits that may result from that legislation. Any amendment shall be made
only upon the mutual consent of the parties, which consent (of either party) may
be withheld for any reason.

                                     * * *
     IN WITNESS WHEREOF the Company has caused this Option to be executed by its
duly authorized officers on its behalf as of ___________________.

                                      -4-
<PAGE>

                                             INSPIRE PHARMACEUTICALS, INC.

                                              By:____________________________

                                              Title:_________________________

                                      -5-<PAGE>

                                                                    EXHIBIT 10.4

            CONSULTATION AND SCIENTIFIC ADVISORY BOARD AGREEMENT

     This Agreement, effective as of March 10, 1995, is between Inspire
Pharmaceuticals, Inc. (the "Company"), a Delaware corporation, and Richard
Boucher, M.D. ("Consultant").

                              W I T N E S S E T H

     WHEREAS, Consultant is a faculty member at the University of North Carolina
at Chapel Hill (the "University");

     WHEREAS, pursuant to the University's regulations concerning professional
consulting and additional workload, Consultant is permitted to enter into
consulting agreements with private companies;

     WHEREAS, the Company desires to have the benefit of Consultant's knowledge
and experience, and Consultant desires to provide consulting services to the
Company, all as hereinafter provided in this Agreement; and

     WHEREAS, the Company desires to have Consultant serve as Chairman of the
Company's Scientific Advisory Board (the "SAB"), and Consultant desires to serve
as Chairman of such SAB;

     NOW, THEREFORE, in consideration of the promises and mutual agreements
hereinafter set forth, the Company and Consultant hereby agree as follows:

     1.   Consultation and Scientific Advisory Board. The Company shall retain
          ------------------------------------------
Consultant as a consultant, and Consultant shall serve the Company as a
consultant and Chairman of the SAB upon the terms and conditions hereinafter set
forth.

                                       1
<PAGE>

     2.   Term. Subject to the terms and conditions hereinafter set forth, the
          ----
term of the Consultant's consulting arrangement and service on the SAB hereunder
(hereinafter referred to as the "Consultation Period") shall commence on the
date hereof, and shall continue for a period of three (3) years; provided,
                                                                 --------
however, that the Consultation Period shall automatically be extended for
-------
additional periods of one (1) year each unless and until either party shall give
the other party thirty (30) days notice of termination prior to the end of the
initial Consultation Period or any one (1) year extension thereof (in the manner
hereinafter provided).

     3.   Consulting and SAB Member Duties.
          --------------------------------

          3.1.   During the Consultation Period, Consultant shall render to
Company or to Company's designee such consulting services in his areas of
expertise and knowledge related to the field of airway diseases and the
development of low molecular weight molecules for therapeutic or diagnostic
purposes (the "Field"), at such times and places as Company may from time to
time reasonably request. The Company shall give Consultant reasonable advance
notice of any services required of him hereunder.

          3.2.   All work to be performed by Consultant for the Company shall be
under the general supervision of the Company.

          3.3.   Consultant shall perform the consulting services in a manner
consistent with the needs of the Company as determined by the Board of Directors
or the President of the Company. All work performed by Consultant to the Company
shall be at times reasonably convenient to the Consultant, and nothing contained
herein shall interfere with Consultant's teaching responsibilities, research
duties or other responsibilities required by the University, his other teaching
and administrative responsibilities or the policies of the

                                       2
<PAGE>

University or the Consultant's Department regarding the scheduling of outside
services (see Exhibit A).

          3.4.   During the Consultation Period, Consultant shall serve as
Chairman of the SAB which will meet periodically to advise the Company on
scientific affairs. As Chairman of the SAB, Consultant will advise the Chief
Executive Officer of the Company regarding the selection of other active and
effective members of the SAB, and will recommend such proposed members to the
Board of Directors for consent and approval.

     4.   Compensation.
          ------------

          4.1.   Consulting Fees.  The Company shall pay to the Consultant the
                 ---------------
following annual consulting fees:

                     Year One:       $40,000
                     Year Two:       $45,000
                     Year Three:     $50,000

     Such consulting fees shall be payable in arrears in twelve (12) equal
monthly installments within ten (10) days of the last day of each month.

          4.2.   Reimbursement of Expenses.  The Company shall reimburse the
                 -------------------------
Consultant for all reasonable and necessary expenses incurred or paid by the
Consultant in connection with, or related to, the performance of his services
under this Agreement. The Consultant shall submit to the Company itemized
monthly statements, in a form satisfactory to the Company, of such expenses
incurred in the previous month. The Company shall pay to the Consultant the
amounts shown on each such statement within thirty (30) days after receipt
thereof. Notwithstanding the foregoing, the Consultant shall not incur total
expenses in excess of $500.00 per month without the prior written approval of
the Company.

                                      -3-
<PAGE>

          4.3.   Benefits.  The Consultant shall not be entitled to any
                 --------
benefits, coverages or privileges, including, without limitation, social
security, unemployment, medical or pension payments, made available to employees
of the Company.

     5.   Equity to Consultant.  In partial consideration of the consulting
          --------------------
services and service on the SAB, the Company shall grant to Consultant founder's
stock consisting of seven hundred thousand (700,000) shares of the Company's
Common Stock, $.001 par value per share, under the terms of a Restricted Stock
Purchase Agreement to be executed by the Company and Consultant.

     6.   Termination.  The Consultation Period shall terminate upon the
          -----------
occurrence of any of the following events:

     (a)  Immediately and without notice upon the death or legal incapacity of
          the Consultant;

     (b)  At the option of the Board of Directors of the Company, with cause,
          immediately upon written notice to the Consultant; or

     (c)  At the option of the Consultant, in his sole discretion, upon ninety
          (90) days prior written notice to the Company.

For the purposes of subsection (b) above, the term "for cause" shall mean (i)
material failure to perform assigned duties for the Company, as described in
this Agreement, or any acts or omissions constituting gross negligence or
willful misconduct in relation to such duties, (ii) commission of a material
breach of any obligation under this Agreement, or (iii) conviction for, pleading
guilty to, or pleading nolo contendere to any crime involving moral turpitude or
any crime that is a felony. In the event of such termination, the Consultant
shall be entitled to payment for services performed and expenses paid or
incurred prior to the effective date of termination, subject to the limitation
on reimbursement of expenses set forth in Section 4.2. Such payments shall
constitute full settlement of any and

                                       4
<PAGE>

all claims of the Consultant under this Agreement for compensation or
reimbursement of expenses against the Company. Notwithstanding the foregoing,
the Company may terminate the Consultation Period, effective immediately upon
receipt of written notice, if the Consultant breaches or threatens to breach any
provision of Sections 7, 8, or 10.

     7.   Cooperation.  The Company shall provide such access to its information
          -----------
and property as may be reasonably required in order to permit the Consultant to
perform his obligations hereunder. The Consultant shall cooperate with the
Company's personnel, shall not interfere with the conduct of the Company's
business and shall observe all rules, regulations and security requirements of
the Company concerning the safety of persons and property.

     8.   Inventions; Proprietary Information and Materials.
          -------------------------------------------------

          8.1. Inventions.
               ----------

               8.1.1.  All inventions, discoveries, tangible materials, computer
programs, data, technology, designs, innovations and improvements (whether or
not patentable and whether or not copyrightable) related to the Field which are
made, conceived, reduced to practice, created, written, designed, discovered or
developed by the Consultant, solely or jointly with others and whether during
normal business hours or otherwise, in the course of performing services
requested by the Company or thereafter if resulting directly or indirectly
derived from Proprietary Information and Materials of the Company (as defined
below) (collectively, "Inventions") shall be the sole property of the Company.
The Consultant hereby assigns to the Company all Inventions and any and all
related patents, copyrights, trademarks, trade names, and other industrial and
intellectual property rights and applications therefor, in the United States and
elsewhere and appoints any officer of the Company as his duly authorized
attorney to execute, file, prosecute and protect the same

                                       5
<PAGE>

before any government agency, court or authority. Upon the request of the
Company and at the Company's expense, the Consultant shall execute such further
assignments, documents and other instruments as may be reasonably necessary or
desirable to fully and completely assign all Inventions to the Company and to
assist the Company in any reasonable manner and at the expense of the Company in
applying for, obtaining and enforcing patents or copyrights or other rights in
the United States and in any foreign country with respect to any Invention.

          8.1.2.  The Consultant shall promptly disclose to the Company all
Inventions and will maintain adequate and current written records (in the form
of notes, sketches, drawings and as may be specified by the Company) to document
the conception and/or first actual reduction to practice of any Invention. Such
written records shall be available to and remain the sole property of the
Company at all times.

          8.1.3.  Consultant shall not perform any duties under this Agreement
on the premises of the University or in any other manner that could result in
claims by the University of rights in any work product generated by Consultant
while performing duties requested by the Company hereunder, unless the Company
and the University have entered into a written agreement that allocates
ownership of such work product, in which case the terms of such agreement shall
on the premises of the University or in any other manner that could result in
claims by the University of rights in any work product generated by Consultant
while performing duties requested by the Company hereunder, unless the Company
and the University have entered into a written agreement that allocates
ownership of such work product, in which case the terms of such agreement shall
prevail in the event of any conflict with this Section 8.1.

          8.2. Proprietary Information and Materials.
               -------------------------------------

               8.2.1.  The Consultant acknowledges that his relationship with
the Company is one of high trust and confidence and that in the course of his
service to the Company he will have access to and contact with Proprietary
Information and Materials (as defined in subparagraph 8.2.2 below). The
Consultant agrees that he will not, during the

                                       6
<PAGE>

Consultation Period or at any time thereafter, disclose to others, or use for
his benefit or the benefit of others, any Proprietary Information or Invention.

               8.2.2.  For purposes of this Agreement, Proprietary Information
and Materials shall mean, by way of illustration and not limitation, all
information and tangible materials (whether or not patentable and whether or not
copyrightable) owned, possessed or used by the Company, including, without
limitation, any Invention, formula, vendor information, customer information,
apparatus, equipment, trade secret, process, research, report, technical data,
know-how, computer program, software, software documentation, hardware design,
technology, marketing or business plan, forecast, unpublished financial
statement, budget, license, price, cost and employee list that is communicated
to, learned of, developed or otherwise acquired by the Consultant in the course
of performing services as a consultant to the Company.

               8.2.3.  The Consultant's obligations under this Section 8.2 shall
not apply to any information or tangible material that (i) is or becomes known
to the general public under circumstances involving no breach by the Consultant
or others of the terms of this Section 8.2, (ii) is generally disclosed to third
parties by the Company without restriction on such third parties, or (iii) is
approved for release by written authorization of the Board of Directors of the
Company.

               8.2.4.  Upon termination of this Agreement or at any other time
upon request by the Company, the Consultant shall promptly deliver to the
Company all records, files, memoranda, notes, designs, data, reports, price
lists, customer lists, drawings, plans, computer programs, software, software
documentation, sketches, laboratory and research notebooks and other documents
(and all copies or reproductions of such materials) and

                                       7
<PAGE>

tangible materials in the possession of Consultant and which were provided to
the Consultant by the Company.

               8.2.5.  The Consultant represents that his retention as a
consultant with the Company and his performance under this Agreement does not,
and shall not, breach any agreement that obligates him to keep in confidence any
trade secrets or confidential or proprietary information of his or of any other
party or to refrain from competing, directly or indirectly, with the business of
any other party. The Consultant shall not disclose to the Company any trade
secrets or confidential or proprietary information of any other party.

               8.2.6.  The Consultant acknowledges that the Company from time to
time may have agreements with other persons or with the United States
Government, or agencies thereof, that impose obligations or restrictions on the
Company regarding inventions made during the course of work under such
agreements or regarding the confidential nature of such work. The Consultant
agrees to be bound by all such obligations and restrictions that are known to
him and to take all action necessary and reasonable to discharge the obligations
of the Company under such agreements.

          8.3. Remedies.  The Consultant acknowledges that any breach of the
               --------
provisions of this Section 8 shall result in serious and irreparable injury to
the Company for which the Company cannot be adequately compensated by monetary
damages alone. The Consultant agrees, therefore, that, in addition to any other
remedy it may have, the Company shall be entitled to seek the specific
performance of this Agreement by the Consultant and to seek both temporary and
permanent injunctive relief (to the extent permitted by law) to prevent the
violation of Consultant's obligations hereunder without the necessity of proving
actual damages.

                                       8
<PAGE>

     9.   Independent Contractor Status.  The Consultant shall perform all
          -----------------------------
services under this Agreement as an "independent contractor" and not as an
employee or agent of the Company. The Consultant is not authorized to assume or
create any obligation or responsibility, express or implied, on behalf of, or in
the name of, the Company or to bind the Company in any manner.

     10.  Noncompetition.
          --------------

          10.1.  Consultant represents and warrants that, as of the date hereof,
except as  set forth in Exhibit A, he is not a party to any agreement or
                        ---------
arrangement that would require him to conduct activities in the Field for
another party or would prevent him from carrying out his obligations to the
Company under this Agreement. During the Consultation Period, Consultant shall
immediately disclose to the Company the occurrence of either of the activities
described in the preceding sentence. If Consultant fails to notify the Company
of such activities within thirty (30) days of the occurrence thereof, the
Company shall have the right to terminate this Agreement immediately upon notice
to Consultant.

          10.2.  Consultant understands the confidential nature of the
information and materials he will acquire or develop in performing his services
under this Agreement. Consultant acknowledges that if such information or
materials were revealed to competitors of the Company, then such disclosure
could cause damage to the Company. Therefore, for the duration of the
Consultation Period and for one (1) year thereafter, Consultant shall not engage
in any activities that would compete with the Company, in the Field, except as
to activities disclosed on Exhibit A or activities for which Consultant has
previously notified the Company under Section 10.1 including without limitation
becoming employed by, serving as a consultant for, serving as a member of a
scientific advisory board (or a comparable organization) for, or acting in any
manner on behalf of any other for-profit enterprise that

                                       9
<PAGE>

conducts activities competitive with those of the Company in the Field, without
first obtaining the written consent of the Company. The Company agrees not to
unreasonably withhold or delay its consent to activities by Consultant in
competitive areas with respect to which the Company either has no business or
does not intend to develop business.

     11.  Notices.  All notices required or permitted under this Agreement shall
          -------
be in writing delivered by a recognized national overnight courier, personal
delivery, or facsimile transmission and shall be deemed effective upon receipt.
The parties shall designate their addresses and facsimile numbers.

     12.  Pronouns.  Whenever the context may require, any pronouns used in this
          --------
Agreement shall include the corresponding masculine, feminine or neuter forms,
and the  singular forms of nouns and pronouns shall include the plural, and vice
versa.

     13.  Entire Agreement.  This Agreement constitutes the entire agreement
          ----------------
between the parties and supersedes all prior agreements and understandings,
whether written or oral,    relating to the subject matter of this Agreement.

     14.  Amendment.  This Agreement may be amended or modified only by a
          ---------
written instrument executed by both the Company and the Consultant.

     15.  Governing Law.  This Agreement shall be construed, interpreted and
          -------------
enforced in accordance with the laws of the State of North Carolina.

     16.  Successors and Assigns.  This Agreement shall be binding upon, and
          ----------------------
inure to the benefit of, both parties and their respective successors and
assigns, including any corporation with which, or into which, the Company may be
merged or which may succeed to its assets or business, provided, however, that
the obligations of the Consultant are personal and shall not be assigned by him.

                                       10
<PAGE>

     17.  Miscellaneous.
          -------------

          17.1.  No delay or omission by the Company or the Consultant in
exercising any right under this Agreement shall operate as a waiver of that or
any other right. A waiver or consent given by the Company or Consultant on any
one occasion shall be effective only in that instance and shall not be construed
as a bar or waiver of any right on any other occasion.

          17.2.  The captions of the sections of this Agreement are for
convenience of reference only and in no way define, limit or affect the scope or
substance of any section of this Agreement.

          17.3.  In the event that any provision of this Agreement shall be
invalid, illegal or otherwise unenforceable, the validity, legality and
enforceability of the remaining provisions shall in no way be affected or
impaired thereby.

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year set forth above.

                              INSPIRE PHARMACEUTICALS, INC.

                              By:   /s/ H. Jeff Leighton
                                  --------------------------

                              Name: H. Jeff Leighton
                              Title: President / CEO

                              CONSULTANT

                                /s/ Richard Boucher, M.D.
                              ------------------------------
                              Richard Boucher, M.D.

                                       11
<PAGE>

                                   EXHIBIT A

                     Disclosure of Activities in the Field
                     -------------------------------------

1.   Glaxo activities include consulting, research and clinical development of
     amiloride for the treatment of lung disease in Cystic Fibrosis. Assistance
     and consulting also provided in study design, FOA discussions, and multi-
     center study of CF patients.

2.   Participation in clinical studies and other consultations regarding gene
     transfer in CF at the present time. Intend to continue studies of gene
     transfer in connection with CF/airway diseases.

3.   University policy varies by Department, but generally, no outside
     Consultation is permitted which would require services in excess of one-
     half day per week.

4.   Consultant shall be permitted to conduct research activities at the
     University under grants sponsored by the Federal Government or any non-
     profit organization.

5.   Consultant shall be permitted to fulfill any teaching duties required by
     the University.

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]